Hutchmed/$HCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hutchmed
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Ticker
$HCM
Sector
Primary listing
Employees
1,780
Headquarters
Hong Kong, Hong Kong
Website
Hutchmed Metrics
BasicAdvanced
$2.8B
30.37
$0.53
0.59
-
Price and volume
Market cap
$2.8B
Beta
0.59
52-week high
$19.50
52-week low
$11.51
Average daily volume
59K
Financial strength
Current ratio
4.651
Quick ratio
4.471
Long term debt to equity
5.719
Total debt to equity
8.111
Interest coverage (TTM)
-6.86%
Profitability
EBITDA (TTM)
-7.491
Gross margin (TTM)
8.93%
Net profit margin (TTM)
77.53%
Operating margin (TTM)
-3.27%
Effective tax rate (TTM)
12.61%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-0.81%
Return on equity (TTM)
46.90%
Valuation
Price to earnings (TTM)
30.367
Price to revenue (TTM)
22.867
Price to book
1.69
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
-230.833
Free cash flow yield (TTM)
-0.43%
Free cash flow per share (TTM)
-0.07
Growth
Revenue change (TTM)
-1.41%
Earnings per share change (TTM)
-1,178.39%
3-year revenue growth (CAGR)
14.53%
10-year revenue growth (CAGR)
15.75%
3-year earnings per share growth (CAGR)
20.99%
10-year earnings per share growth (CAGR)
15.71%
Bulls say / Bears say
ORPATHYS® (savolitinib) in combination with TAGRISSO® received China approval for EGFR-mutant NSCLC with MET amplification on June 30, 2025, triggering an $11 million milestone payment from AstraZeneca and expanding the company’s addressable lung cancer market (SEC EDGAR)
Takeda’s ex-China in-market sales of FRUZAQLA® grew 25% to $162.8 million in H1 2025, reflecting robust international commercial momentum across more than 30 countries (SEC EDGAR)
The company reported net income attributable of $455.0 million and held $1.36 billion cash as of June 30, 2025, providing strong financial resources for ongoing R&D and strategic initiatives (SEC EDGAR)
Oncology/Immunology consolidated revenue fell 15% year-on-year to $143.5 million in the first half of 2025, signaling softness in its core segment (SEC EDGAR)
ELUNATE in-China sales decreased by 29% to $43.0 million in H1 2025 due to intensifying competitive pressures from generics and combination therapies (SEC EDGAR)
Net income surge to $455.0 million was driven by a one-off $416.3 million divestment gain, masking a 9% decline in total revenue to $277.7 million in H1 2025 (SEC EDGAR]Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hutchmed stock?
Hutchmed (HCM) has a market cap of $2.8B as of October 05, 2025.
What is the P/E ratio for Hutchmed stock?
The price to earnings (P/E) ratio for Hutchmed (HCM) stock is 30.37 as of October 05, 2025.
Does Hutchmed stock pay dividends?
No, Hutchmed (HCM) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next Hutchmed dividend payment date?
Hutchmed (HCM) stock does not pay dividends to its shareholders.
What is the beta indicator for Hutchmed?
Hutchmed (HCM) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.